SecBot SecBot
PRESS-RELEASE ·Filed Jun 1, 2026

BIIB

Biogen Inc.; UCB
MIXED
Impact 5/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ◆ Mixed

The data are directionally positive for DZP's approvability, but the non-multiplicity-controlled secondary endpoints and need for a second Phase 3 trial (PHOENYCS FLY)mean material regulatory catalyst is likely >2 years away. Monitor enrollment updates and eventual FLY topline; no near-term trading catalyst from this publication.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$192.22
T+0 close · Jun 1, 2026 · via day close
Latest settled
+14.38%
T+60 · $219.85
Vs SPY
+13.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $192.22entry
  2. T+1 · 6mo ago −1.85%α −2.00% · $188.66
  3. T+5 · 5mo ago +1.63%α +4.38% · $195.34
  4. T+20 · 5mo ago +12.70%α +15.01% · $216.63
  5. T+60 · 3mo ago +14.38%α +13.40% · $219.85

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Biogen and UCB announced publication of full Phase 3 PHOENYCS GO results for dapirolizumab pegol (DZP) in The Lancet, showing a statistically significant improvement at Week 48 on the BICLA composite endpoint (50% vs 35%, p=0.011) in moderate-to-severe active SLE. However, the first key secondary endpoint at Week 24 was not met, disqualifying subsequent multiplicity-controlled comparisons, and the ongoing confirmatory PHOENYCS FLY trial is still recruiting with no regulatory submissions imminent. The data are incrementally positive but the path to approval remains contingent on a second confirmatory readout.

Key Facts

  • Primary endpoint (BICLA response at Week 48) met: 50% for DZP + SOC vs 35% for placebo + SOC (p=0.011)
  • First key secondary endpoint (BICLA response at Week 24) was not met, so subsequent outcomes were not controlled for multiplicity
  • Serious TEAEs were lower with DZP + SOC (10.0%) vs placebo + SOC (14.8%); discontinuations low in both arms (4.7% vs 3.7%)
  • PHOENYCS FLY confirmatory Phase 3 trial is currently recruiting; intended to support future regulatory filings
  • DZP is an investigational Fc-free CD40L inhibitor, not approved by any health authority
  • Biogen's market cap is $28.9B; UCB generated €7.7B revenue in 2025

Financial Impact

No financial terms disclosed; DZP is pre-commercial. A positive but incomplete Phase 3 readout does not change near-term revenue/EPS estimates for Biogen.

r_and_dpipeline_value

Risk Factors

  • First key secondary endpoint (Week 24) failure weakens the overall statistical package and may concern regulators
  • Confirmatory trial (PHOENYCS FLY) has not yet read out; development failure is still possible
  • DZP is a collaboration asset, Biogen shares economics with UCB, limiting solo upside for BIIB
  • No regulatory filings have been submitted or announced; timeline to potential approval is uncertain

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
56% bullish (43 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3304009

Track record

34 reports on BIIB

Performance horizon

10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
  4. Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  5. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  6. Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
  7. Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
  8. Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
  9. Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
  10. Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (11h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026